Symptom resolution with CAS + IMD according to antibody profile
cough, IgA, fatigue, fever
The results of subgroup analyses based on Ig status at baseline are presented in Fig. Treatment effect trajectories based on baseline antibody profile. (Further analyses of symptoms resolution focused on patients who were seropositive at baseline to explore potential differences in response to treatment within this subgroup. Analysis by the presence/absence of NAbs at baseline demonstrated a significant treatment benefit of CAS + IMD in patients who lacked NAbs, while there was no difference in those who were NAb-positive (Fig. In analyses of patients receiving placebo only, the presence of IgA at baseline impacted symptom evolution for cough and possibly fatigue, whereas the presence of IgG had a favorable effect on fever and possibly fatigue (Supplemental Fig. We also examined the effects of CAS + IMD on symptom evolution in patients who demonstrated late seroconversion (i.e., seronegative at baseline but seropositive for IgG anti-N by day 29; Fig. Treatment effect trajectories based on seropositivity at baseline and seroconversion by day 29. Treatment effect trajectories for each symptom of the Symptoms Evolution of COVID-19 instrument were obtained using a two-step approach and analyzed by baseline serology status and seroconversion (see Statistical Methodology for more details). Baseline seronegative patients who seroconverted by day 29 versus seropositive patients at baseline were considered in the analysis of treatment effect trajectories. Curve estimates are indicated by the blue lines in the center, and 95% confidence bands are indicated by the red lines. 